Evidence map›Paper›PMID 22850786›Full record

ReviewNature reviews. Drug discovery2012

Revisiting lab-on-a-chip technology for drug discovery.

Pavel Neuži, Stefan Giselbrecht, Kerstin Länge, Tony Jun Huang, Andreas Manz

Abstract readReview
In one paragraph

Review in Nature reviews. Drug discovery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers.

0numbers the graph read from it
0cells of the map it votes in
144citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

144 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

84 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Pavel NeužiKorean Institute of Science and Technology in Europe (KIST Europe GmbH), Campus E71, 66123 Saarbrücken, Germany.
Stefan Giselbrecht
Kerstin Länge
Tony Jun Huang
Andreas Manz

Funding

On-Chip Optofluidic Laser Scanning Confocal Microscope for Early Cancer DetectionDP2OD007209 · OD · PENNSYLVANIA STATE UNIVERSITY, THE · PI HUANG, TONY JUN · 2010 to 2010
$2.2M
NIH HHS DP2 OD007209
6 · The paper itself

Abstract

The field of microfluidics or lab-on-a-chip technology aims to improve and extend the possibilities of bioassays, cell biology and biomedical research based on the idea of miniaturization. Microfluidic systems allow more accurate modelling of physiological situations for both fundamental research and drug development, and enable systematic high-volume testing for various aspects of drug discovery. Microfluidic systems are in development that not only model biological environments but also physically mimic biological tissues and organs; such 'organs on a chip' could have an important role in expediting early stages of drug discovery and help reduce reliance on animal testing. This Review highlights the latest lab-on-a-chip technologies for drug discovery and discusses the potential for future developments in this field.

Indexed as

Lab-On-A-Chip DevicesMicrofluidic Analytical TechniquesModels, BiologicalAnimalsAnimal Testing AlternativesDrug DesignDrug DiscoveryHumansMicrotechnology

Identifiers

PMID22850786
PMCPMC6493334

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.